This cohort study examines the rates of mild cognitive impairment and probable dementia among initiators of an angiotensin II receptor blocker (ARB) vs angiotensin-converting enzyme inhibitor (ACEI)–based antihypertensive medication regimen. The gene discussed is ACE; the disease is dementia.